SARS2 and COVID-19: Longitudinal data were collected for 95 individuals with primary SARS2 infection in 2020, before the availability of COVID-19 vaccines, with sampling including nasopharyngeal (NP) swabs for SARS2 RNA, serum, and peripheral blood mononuclear cells (PBMCs), all collected in the context of a randomized, controlled clinical trial (ACTIV-2/A5401, ClinicalTrials.gov NCT04518410).